Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche experiences second failure in Alzheimer's disease
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(95)
•••
Comment by Quentin30on Nov 15, 2022 6:30pm
165 Views
Post# 35101572

RE:RE:RE:RE:Roche experiences second failure in Alzheimer's disease

RE:RE:RE:RE:Roche experiences second failure in Alzheimer's diseaseNoteable... you have bombarded this bb with hopium about a buyout... for how many years now... I think at least 3.. and what has the PPS done in that time..?

Watch the latest video interview with Matt. He 'hopes' to share news of a partnership with shareholders with the release of details of Phase III trials... which he claims are 6-9 months out.

Now why would he talk about partnership and NOT buyout do you think..?

It's you who spreads nonsense here. People want to hear good news and your spoonfed diatribe on other company buyouts gets folk counting their chickens before the eggs are laid. Scams a resuccessful because people are greedy and they want to believe. FTX ? Matt is not talking buyout... so who is right, YOU or the CEO of ONCY.?

just sayin'
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities